Cytodyn Inc (CYDY)

[Dr Zaius]

Tadamitsu Kishimoto, MD, PhD, of the Department of Immune Regulation at the Immunology Frontier Research Center at Osaka University, Osaka, Japan disagrees with your theory,

"His study, published online August 21 in PNAS, also revealed lower serum IL-6 levels among people with COVID-19 compared to patients with bacterial ARDS or sepsis.

Kishimoto drew a distinction, however: COVID-19 patients can develop severe respiratory failure, suggesting a distinct immune reaction compared to patients with bacterial sepsis. SARS-CoV-2 directly infects and activates endothelial cells rather than macrophages, as occurs in sepsis.

For this reason, Kishimoto said, "SARS-CoV-2 infection causes critical illness and severe dysfunction in respiratory organs and induces a cytokine storm," even in the setting of lower but still elevated serum IL-6 levels.

Dr. Kishimoto's study is much more robust (N=127 vs N=46) than the study referenced in Medscape. The study is more comprehensive and nuanced than the Dutch study and debunks it immediately.

https://www.pnas.org/content/117/36/22351

Antivirals do not work for everyone and are susceptible to failure once the virus mutates.

I conclude that it appears certain that Leronlimab will be needed for severe/critical patients.

Nader should continue to focus on CD12 while keeping the ball rolling on the HIV BLA.